TR200103185T2 - MEK enzimleri inhibitörleri olarak kinolin türevleri. - Google Patents

MEK enzimleri inhibitörleri olarak kinolin türevleri.

Info

Publication number
TR200103185T2
TR200103185T2 TR2001/03185T TR200103185T TR200103185T2 TR 200103185 T2 TR200103185 T2 TR 200103185T2 TR 2001/03185 T TR2001/03185 T TR 2001/03185T TR 200103185 T TR200103185 T TR 200103185T TR 200103185 T2 TR200103185 T2 TR 200103185T2
Authority
TR
Turkey
Prior art keywords
carbon atoms
optionally
pyrimidinyl
pyridinyl
alkyl
Prior art date
Application number
TR2001/03185T
Other languages
English (en)
Inventor
Hopkinson Gibson Keith
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TR200103185T2 publication Critical patent/TR200103185T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Mevcut bulus belli kinolin türevlerinin ilaçlarin hazirlanmasinda, özellikle özel kinaz enzimlerinin, özellikle MEK enzimlerinin, inhibitörleri olarak kullanimi ile ve ayni zamanda yeni kinolin türevleri ile ilgilidir. Bulusun diger yönleri bahsedilen bilesiklerin kullanilmasiyla kanser gibi ilerleyen hastalik tedavisi için farmasötik bilesimleri ve yöntemleri kapsar.
TR2001/03185T 1999-05-08 2000-05-03 MEK enzimleri inhibitörleri olarak kinolin türevleri. TR200103185T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9910580.1A GB9910580D0 (en) 1999-05-08 1999-05-08 Chemical compounds

Publications (1)

Publication Number Publication Date
TR200103185T2 true TR200103185T2 (tr) 2002-05-21

Family

ID=10852989

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03185T TR200103185T2 (tr) 1999-05-08 2000-05-03 MEK enzimleri inhibitörleri olarak kinolin türevleri.

Country Status (16)

Country Link
US (1) US6638945B1 (tr)
EP (1) EP1178965B1 (tr)
JP (1) JP2002544194A (tr)
KR (1) KR20020000803A (tr)
CN (1) CN1350524A (tr)
AT (1) ATE250582T1 (tr)
AU (1) AU4589200A (tr)
BR (1) BR0010366A (tr)
CA (1) CA2371469A1 (tr)
DE (1) DE60005504T2 (tr)
GB (1) GB9910580D0 (tr)
IL (1) IL146319A0 (tr)
NO (1) NO20015447L (tr)
TR (1) TR200103185T2 (tr)
WO (1) WO2000068199A1 (tr)
ZA (1) ZA200108969B (tr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002017952A2 (en) 2000-09-01 2002-03-07 Van Andel Institute Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
AU2002210714A1 (en) * 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents
EP1337513A1 (en) 2000-11-02 2003-08-27 AstraZeneca AB 4-substituted quinolines as antitumor agents
US6603005B2 (en) 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
US6602884B2 (en) 2001-03-13 2003-08-05 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them
AU2002255852B2 (en) * 2001-03-22 2006-11-09 Van Andel Research Institute Anthrax lethal factor inhibits tumor growth and angiogenesis
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
ES2389258T3 (es) * 2003-06-17 2012-10-24 Millennium Pharmaceuticals, Inc. Composiciones y métodos para inhibir TGF-s
EP2612853A1 (en) * 2003-09-26 2013-07-10 Exelixis Inc. c-Met modulators and methods of use
US20090239936A1 (en) 2006-05-15 2009-09-24 Yoshikazu Sugimoto Prophylactic and Therapeutic Agent for Cancer
MX2009012117A (es) * 2007-05-09 2009-11-23 Pfizer Composiciones y derivados heterociclicos sustituidos y su uso farmaceutico como antibacterianos.
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
CA2765823A1 (en) * 2009-06-25 2010-12-29 Amgen Inc. Tricyclic heterocyclic compounds as mediators of p13k activity
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2598660B1 (en) 2010-07-26 2017-03-15 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
EP3632208A1 (en) 2013-06-13 2020-04-08 Biomatrica, INC. Cell stabilization
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
EP3154338B1 (en) 2014-06-10 2020-01-29 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
KR20180086187A (ko) 2015-10-05 2018-07-30 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료
JP6827048B2 (ja) 2015-12-08 2021-02-10 バイオマトリカ，インク． 赤血球沈降速度の低下
CN106220560A (zh) * 2016-07-27 2016-12-14 华侨大学 一种多取代喹啉衍生物的制备方法
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP2019533641A (ja) 2016-09-08 2019-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態およびその使用
KR20230081932A (ko) 2021-11-30 2023-06-08 주식회사 메타뷰 실내 위치 측위 정보를 모니터링하는 고온환경 스마트 팩토리 안전관리 시스템 및 그 방법
KR102557537B1 (ko) 2022-08-25 2023-07-20 김형미 개선된 통신 방식을 활용한 스마트 도어 제어 방법, 장치 및 시스템
KR102498884B1 (ko) 2022-11-04 2023-02-10 주식회사 레딕스 현장 작업자와 화물차 기사의 안전관리를 위한 안전관리 시스템

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE317376B (tr) 1961-07-10 1969-11-17 Roussel Uclaf
FR2077455A1 (en) 1969-09-03 1971-10-29 Aries Robert 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials
US3936461A (en) 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
FR2498187A1 (fr) 1981-01-16 1982-07-23 Rhone Poulenc Sante Procede de preparation d'amino-4 chloro-7 quinoleines
IL81307A0 (en) 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2114727C (en) 1991-08-02 1996-12-10 Mikel P. Moyer Quinoline derivatives as immunostimulants
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
DE69622183D1 (de) 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
DK0912559T3 (da) 1996-07-13 2003-03-10 Glaxo Group Ltd Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
ATE300521T1 (de) * 1996-09-25 2005-08-15 Astrazeneca Ab Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
CN1163475C (zh) 1997-07-01 2004-08-25 沃尼尔·朗伯公司 4-溴或4-碘苯基氨基苯氧肟酸衍生物及其作为mek抑制剂的用途
ES2274572T3 (es) 1997-07-01 2007-05-16 Warner-Lambert Company Llc Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek.
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
EP1117659B1 (en) 1998-09-29 2003-12-03 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
BR9914164A (pt) 1998-09-29 2001-06-26 American Cyanamid Co Composto, método para o tratamento, inibição do crescimento de, ou erradiacação de um neoplasma, e de doença de rim policìstico, em um mamìfero em necessidade do mesmo, composição farmacêutica, e, processo para preparar um composto

Also Published As

Publication number Publication date
EP1178965B1 (en) 2003-09-24
BR0010366A (pt) 2002-02-13
DE60005504D1 (de) 2003-10-30
NO20015447L (no) 2001-12-12
CN1350524A (zh) 2002-05-22
CA2371469A1 (en) 2000-11-16
AU4589200A (en) 2000-11-21
KR20020000803A (ko) 2002-01-05
DE60005504T2 (de) 2004-06-24
US6638945B1 (en) 2003-10-28
ATE250582T1 (de) 2003-10-15
WO2000068199A1 (en) 2000-11-16
GB9910580D0 (en) 1999-07-07
NO20015447D0 (no) 2001-11-07
ZA200108969B (en) 2003-01-30
EP1178965A1 (en) 2002-02-13
IL146319A0 (en) 2002-07-25
JP2002544194A (ja) 2002-12-24

Similar Documents

Publication Publication Date Title
TR200103185T2 (tr) MEK enzimleri inhibitörleri olarak kinolin türevleri.
IL146326A0 (en) Quinoline derivatives as inhibitors of mek enzymes
EE200100589A (et) Kinoliini derivaadid MEK ensüümide inhibiitoritena
HUP0104816A2 (hu) 3-Azabiciklo[3.1.0]hexán-származékok mint ópiát receptor ligandumok és eljárás előállításukra
NO2015020I2 (no) Ceritinib eller et farmasøytisk akseptabelt salt derav
RU95108387A (ru) Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина
TW342390B (en) Carbocyclic and heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
FI915970A0 (fi) Laekemedel, som aer nyttiga vid vaord av cancer och som har antihistaminegenskaper.
ATE25682T1 (de) Indol-3-carboxamid-derivate.
NO163855C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive arylcyklobutylalkylaminer.
NO171786C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater
SE8800863L (sv) 3-(2-haloalkyl)-1,4-oxatiiner och 2-(2-haloalkyl)1,4-ditiiner och bahandling av leukemi och tumoerer daermed
EA200101170A1 (ru) Галоидпроизводные 9-деоксо-9а-аза-9а-гомоэритромицина а
JO1676B1 (en) Extra compounds indinol II
HUP0001727A2 (hu) Új 1-aza-2-alkil-6-aril-cikloalkán-származékok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények
DE69301639D1 (de) Tetrahydronaphtalenderivate, ihre Herstellung und ihre therapeutische Verwendung